Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition.

Oncogene·2026
Same author

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

Cell death & disease·2025
Same author

Confirmation by conformation: rescue of mutant p53 in AML.

Blood·2025
Same author

Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

Cancer research·2025
Same author

CDK11 inhibition induces cytoplasmic p21<sup>WAF1</sup> splice variant by p53 stabilisation and SF3B1 inactivation.

Molecular oncology·2025
Same author

The legacy of a gentleman scientist: Pierre Hainaut.

Cell death and differentiation·2025
Same journal

Cannabis and Cannabidiol, GLP-1 Receptors, and Autophagy: The Burgeoning Link Between Cognitive Neurodegeneration With Alzheimer's Disease and Metabolic Disorders.

Discovery medicine·2026
Same journal

The Urgent Need to Assess and Prevent the Deposits of Microplastics and Nanoplastics in Our Brain.

Discovery medicine·2025
Same journal

Bridging the Translational Gap: Prioritizing the Spontaneous Canine Osteoarthritis Model for Preclinical Studies.

Discovery medicine·2025
Same journal

Harnessing the Power of Chlorogenic Acid: Inhibiting IL-2-Mediated Treg Upregulation to Combat Post-Traumatic Osteomyelitis.

Discovery medicine·2025
Same journal

The Relationship of <i>MAPK10P</i> Gene Polymorphism With P-Wave Peak Time and P-Wave Dispersion in Elderly Patients With Paroxysmal Atrial Fibrillation.

Discovery medicine·2025
Same journal

Curcumin Attenuates PD-L1-Positive Neutrophil-Induced T-Lymphocyte Apoptosis and Alleviates Lung Injury During Sepsis in Rats.

Discovery medicine·2025
See all related articles

Related Experiment Video

Updated: May 29, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

New insights into p53 based therapy.

David P Lane1, Christopher John Brown, Chandra Verma

  • 1p53 Laboratory, A*STAR, and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Discovery Medicine
|September 1, 2011
PubMed
Summary
This summary is machine-generated.

Cancer often involves the p53 tumor suppressor pathway. New research in animal models and with p53-activating drugs offers insights into p53

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Related Experiment Videos

Last Updated: May 29, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 tumor suppressor pathway is frequently inactivated in human cancers.
  • Inactivation occurs via p53 gene mutations or disruption of essential regulatory pathways.
  • Understanding p53's role is critical for cancer therapy.

Purpose of the Study:

  • To explore novel therapeutic strategies targeting the p53 pathway in cancer.
  • To investigate the dual therapeutic and toxic effects of p53 activation.
  • To leverage new findings for improved cancer treatment.

Main Methods:

  • Utilizing data from animal cancer models.
  • Employing p53-activating small molecules.
  • Analyzing therapeutic and toxicological outcomes.

Main Results:

  • New insights into the mechanisms of p53 pathway inactivation in cancer.
  • Demonstration of therapeutic potential of p53-activating agents.
  • Identification of challenges related to p53 activation therapies.

Conclusions:

  • Targeting the p53 pathway holds significant promise for cancer treatment.
  • Further research is needed to optimize p53-based therapies and mitigate toxicity.
  • Animal models and small molecule activators are valuable tools for p53 research.